

Johnson & Johnson (JNJ)
Rating: 2/A
QUARTERLY EARNINGS
Pharmaceuticals
Analyst: Erick Noensie

Current Rating	2/A
Previous Rating	P/A
Last Rating Change	1/24/2019

Previous Close	\$146.73
Projected 12 Mo Trading Range	
Low	\$124.00 -15.49%
High	\$165.00 12.45%
52w Hi/Low	\$157.0 \$109.2
YTD % Change	0.59%

	2019a	2020e	2021e
EPS (\$)	8.68	7.74	8.98
% chg		-10.83%	16.02%
P/E	25.88	19.09	16.29
Consensus		7.72	9.04
Fiscal Year End		12/31/2020	

Market Cap (\$m)	386,574.1
Shares Out (m)	2,634.6

Annual Dividend	\$4.04
Dividend Yield	2.75%

Book Value/ Shares	\$22.59
Price/Book Value	6.45
Price/Sales	4.76
Debt/Total Cap (%)	30.87
LT Growth Rate (%)	5.92

Source: FactSet Research Systems Inc.

Publishing Analyst Disclosure: The analyst does not have a position in the security

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases and vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

UPDATING MODEL; PHARMA RESILIENT, DEVICE RECOVERY ANTICIPATED
Conclusion

1Q revenues of \$20.7B were above consensus of \$19.7B (+4.8% operationally), and EPS of \$2.30 was above consensus of \$2.02. Pharmaceuticals grew 4.8% and appeared resilient with some products coming in ahead of expectations. The consumer group grew 11% in the quarter, including a 700bp stocking benefit mostly from OTC flu-related products. JNJ lowered guidance for full year organic revenue growth to a midpoint of -1.25% from +5.5% prior, based almost solely on the pandemic hit to the medical device segment, which declined 7% in the quarter. We anticipate a majority of elective procedures are being deferred and will return over the next 12-18 months. JNJ is developing a vaccine for COVID-19, and although the company is not a market leader in vaccines, it does have a presence in the category, which includes some advanced technologies. While management believes it could have Emergency Use Authorization by early 2021, we are more cautious on overall vaccine development timelines and its financial significance, as the company anticipates offering the vaccine on an emergency non-profit basis. Guidance for cash flow was lowered to "teens", which implies a reduction of \$2-3B from prior guidance; however, management raised the dividend by 6.3%, demonstrating the company's strong balance sheet. We believe the recovery in elective procedures will be the key area to watch over the near- to mid-term as it pertains to JNJ earnings. We lower our EPS estimates but maintain our valuation range and we do not yet believe the stock is positioned to significantly outperform the overall healthcare sector.

Reported EPS: \$ 2.30

Consensus: \$ 2.02

Thesis

Although we are positive on JNJ's diversification and stability, we see a mixed outlook to the overall business and we watch for signs of improvement. In its pharmaceutical division, JNJ has a solid group of therapeutic growth drivers, but this is offset by increasing price pressure and patent expirations. JNJ's Device group appears to have durable growth, but is also curtailed by price pressure and a lack of strong innovation. Our valuation analysis suggests JNJ shares are valued, with only modestly positive risk/reward to our expected trading range. We believe the fundamentals at JNJ have the potential to improve during 2019 and we would watch for more signs of a positive turn or a more attractive entry point to turn constructive on the shares.

Details
Key Metrics Analysis:

- **EPS:** JNJ reported 1Q20 adjusted EPS of \$2.30 (9.5% q/q reported), beating consensus of \$2.02.
- **Revenue:** JNJ reported 1Q20 revenue of \$20.7B (5.6% q/q organic), above consensus \$19.7B. COVID-19 had a -80bp impact to growth, with headwinds in the Medical Device segment offsetting benefits in Pharmaceuticals and Consumer Health. Currency negatively impacted sales by -1.5%.
- **Operating Margin:** 1Q20 operating margin was 35.0%, an improvement of 70bps q/q. Margin expansion was driven by milestone payments in the Pharmaceutical sector, partially offset by a decline in the Medical Device margin related to COVID-19 and tough comps from a one-time gain during 2019 in Consumer Health.
- **Segment Details:**
 - Pharmaceutical revenues of \$11.1B (10.2% q/q organic), beat consensus \$10.5B, and were driven by double-digit growth across nine key products. Stocking by healthcare providers and wholesalers in preparation for the impact of COVID-19 added 100bps to growth. US sales grew by 8.7% q/q and international sales increased by 12.0% q/q. Immunology grew 13.1% q/q driven by Stelara in Crohn's disease, Tremfya, and Simponi. Oncology grew 21.8%, driven by Darzalex, and Imbruvica. Infectious Diseases grew 11.0% q/q and Neuroscience was up 3.1% q/q. Cardiovascular revenue declined -13.1% q/q, due to increased rebates on Xarelto, partially offset by longer scripts due to COVID-19 demand. Pulmonary Hypertension revenue increased 14.7% q/q, driven by market share gains from Opsumit and Upravi, in addition to increased demand due to COVID-19.
 - Medical Device revenues of \$5.9B (-4.8% q/q organic), was above

consensus of \$5.6B. The delay of elective procedures reduced growth by an estimated -750bps to -800bps which was partially offset by stocking in the Asia Pacific in anticipation of procedures returning. Vision sales of \$1.1B declined -4.5% q/q. Double digit US growth in daily disposables was offset by the impact of COVID-19 and the last of the negative impact of forward buying in Japan during previous quarters. Interventional Solutions revenue increased 0.4% q/q. Surgery sales of \$2.1B declined -10.5%. Orthopedic sales of \$2.0B fell -6.5% q/q and were a little lighter than consensus of \$2.1. JNJ estimates COVID-19 had a -750bp impact on orthopedic growth. Knee sales declined by -6.1% q/q, and hips were down -5.6% q/q. Trauma sales declined -3.5% and Spine fell -10.6% q/q with JNJ noting that they lost share in Spine during the quarter. JNJ continued to see pricing pressure in all orthopedic categories, with hip pricing down -2% and knees down -1%. US Medical Devices sales declined -4.3% q/q, and international sales fell -5.3% q/q, excluding acquisitions and divestures.

- Consumer sales of \$3.6B (11.0% q/q organic) were above consensus of \$3.4B. Consumer growth experienced a 700bp benefit related to stocking, primarily in the US OTC business. This is expected to partially reverse throughout the remainder of the year. Skin Health/Beauty increased 3.5% q/q, driven by Neutrogena e-commerce growth in the US, while sales in China and Japan declined due to COVID-19. Baby Care declined -4.9% q/q, due to the Baby Center divestiture, SKU rationalization, and COVID-19. OTC was up 25.8%, primarily due to COVID-19 pantry stocking, and a strong flu and allergy season. Oral care grew 9.8% q/q, Women's health grew 9.2% q/q and Wound Care increased 11.8% q/q. Consumer growth in the US was up 21.0% q/q, while international revenue was up 3.9% q/q.

Key Product Metrics (actual vs. consensus):**Oncology**

- Imbruvica: \$1.03B vs. \$945M (34% q/q)
- Darzalex: \$937M vs. \$928M (52% q/q)
- Zytiga: \$690M vs. \$695M (4% q/q)

Immunology

- Stelara: \$1.8B vs. \$1.5B (31% q/q)
- Remicade: \$990M vs. \$904M (-9% q/q)

Cardiovascular/ Metabolism/ Other



- Invokana: \$175M vs. \$158M (-13% q/q)
- Xarelto: \$527M vs. \$438M (-3% q/q)

Guidance: JNJ reduced FY20 adjusted EPS guidance to \$7.50-7.90, from prior expectations of \$8.95-9.10, compared to consensus of \$7.94. The new EPS guidance represents a reported decline of -13.6% to -9.0% y/y, compared to prior expectations of 3.1% to 4.8% y/y growth. On an operational basis adjusted EPS is expected to fall -11.9% to -7.3% y/y. FY20 sales are now expected to be between \$77.5-80.5B, down from previous sales guidance of \$85.4-86.2B, but bracketing consensus of \$79.4B. The updated revenue guidance represents organic sales growth of -3.0% to +0.5% y/y, compared to prior expectations of +5.0-6.0% y/y organic growth. The bulk of the revision was driven by the Medical Device segment where JNJ estimates a \$4.0-7.0B negative impact on operational sales from COVID-19. The pharmaceuticals business is expected to be resilient with a small impact from delayed doctor visits and new patient starts. JNJ is maintaining the expectations set for the Consumer Health segment in January, as the benefit from stocking in 1Q20 is not expected to continue throughout the year, and JNJ sees upside in OTC offsetting weakness in other areas. Adjusted pre-tax margins are expected to decline -100bps during the year driven by higher manufacturing costs related to COVID-19, partially offset by \$2B in spending reductions. The effective tax rate guidance was widened to 16.5-18.0%, due to uncertainties around the timing of the economic recovery. Guidance for cash flow was lowered to "teens", which implies a reduction of \$2-3B from prior guidance. Guidance assumes COVID-19 has a short-term impact with the largest impact to sales occurring in 2Q20.

Medical Devices:

All three main competitors in the orthopedics hips and knees segment, JNJ, Stryker (SYK, 2/A) and Zimmer (ZBH, 1/B), were hit in 1Q20 and we expect similar declines in 2Q20. However, we expect a majority of these procedures to be deferred and should return over the next 12-18 months. Note that during the financial crisis in 2008-2010, the decline in knee procedures was relatively short-lived, and hip procedures were relatively resilient, supporting the prospect of a recovery in this case.

Quarter-over-quarter growth shows steep declines in 1Q20 for all major competitors in hip and knee replacements (Source: company reports).



BASE CASE MODEL

A basic model reflecting management's guidance for organic sales growth of -3% to +0.5% in 2020 (corresponding to reported y/y change of -5.5% to -2%), suggests that 2020-2022 estimates are achievable. The downgraded guidance included a \$4-7B hit to revenues based on the medical device segment, which will be the key segment to watch during the recovery period. Consensus 2022 sales estimates have been reduced to \$91.9B from \$94.0B suggesting a lowered bar going forward.

Base Case Model

		2018	2019	2020	2021	2022	2020-2022 CAGR	% of '22 Sales	Growth Attribution*
Income Statement (Mn)									
Selected Sales Items									
Pharmaceuticals		40,734	42,198	44,414	47,339	49,332	5.4%	54%	40%
	y/y	12.4%	3.6%	5.3%	6.6%	4.2%			
Medical Devices		26,994	25,963	20,614	26,184	27,136	14.7%	30%	53%
	y/y		-3.8%	-20.6%	27.0%	3.6%			
Consumer		13,853	13,898	14,049	14,603	15,012	3.4%	16%	8%
	y/y	1.8%	0.3%	1.1%	3.9%	2.8%			
Tremfya		544	1,012	1,297	1,551	1,783	17.3%	2%	4%
	y/y	nm	86.0%	28.1%	19.6%	15.0%			
Total Sales		81,581	82,059	79,540	86,675	91,948	7.5%		
	y/y	6.7%	0.6%	-3.1%	9.0%	6.1%			
Gross Profit		56,942	57,444	55,584	61,867	62,969	6.4%		
	y/y	8.8%	0.9%	-3.2%	11.3%	1.8%			
SG&A		21,843	22,169	21,349	12,800	23,639	5.2%		
	y/y	2.4%	1.5%	-3.7%	-40.0%	84.7%			
R&D		10,591	10,775	10,911	11,802	12,172	5.6%		
	y/y	16.4%	1.7%	1.3%	8.2%	3.1%			
EBITDA		31,023	28,086	26,920	30,871	32,904	10.6%		
	y/y	23.0%	-9.5%	-4.2%	14.7%	6.6%			
Net Income		22,315	23,310	20,606	23,871	26,302	13.0%		
	y/y	11.4%	4.5%	-11.6%	15.8%	10.2%			
Shares Out		2,729	2,684	2,674	2,633	2,644	-0.6%		
	y/y	-0.6%	-1.6%	-0.4%	-1.5%	0.4%			
EPS		8.18	8.68	7.71	9.07	9.95	13.6%		
	y/y	12.1%	6.1%	-11.2%	17.7%	9.7%			
Margins & Other Metrics									
Gross Margin		69.8%	70.0%	69.9%	71.4%	68.5%	-70 bp/y		
R&D / Sales		13.0%	13.1%	13.7%	13.6%	13.2%	-25 bp/y		
SG&A / Sales		26.8%	27.0%	26.8%	14.8%	25.7%	-55 bp/y		
EBITDA Margin		38.0%	34.2%	33.8%	35.6%	35.8%	95 bp/y		
Tax Rate		16.4%	17.4%	17.1%	17.4%	17.1%	-5 bp/y		
Net Income Margin		27.4%	28.4%	25.9%	27.5%	28.6%	135 bp/y		
Net Debt / EBITDA		0.4	0.4	0.3					
Cash Flow									
Capex / Sales		4.5%	4.3%	4.3%	4.3%	4.3%	0 bp/y		
Free Cash Flow		18,531	19,887	16,132	21,132	23,893	21.7%		
Dividend Payout		42.5%	42.5%	-	-	-			

* Percent of total company revenue growth generated from individual product line

VALUATION

JNJ's valuation is in the range with its large cap pharmaceutical and medical device peers on multiple metrics including PE, PEG, EV/sales and EV/EBITDA suggesting that there is only modestly positive upside in JNJ shares based on valuation alone.

Pharmaceuticals and medical devices comparables table:

Comparables (2021 metrics)	JNJ	MRK	PFE	ABT	MDT	Median
Market Cap (\$Bn)	386.6	205.8	200.0	156.1	130.1	200.0
EV (\$Bn)	396.1	226.4	242.0	170.7	143.9	226.4
PE	16.2	13.6	13.4	24.0	17.0	16.2
PEG (2 Year Growth)	1.2	1.1	6.1	1.1	0.5	1.1
EV / Sales	4.6	4.5	5.6	4.9	4.6	4.6
EV / EBITDA	13.0	10.5	13.8	19.5	13.2	13.2
FCF Yield (on EV)	5.6%	6.8%	6.3%	4.3%	5.4%	5.6%
Dividend Yield	2.9%	3.1%	4.4%	1.8%	2.4%	2.9%
Net Debt / EBITDA	0.3	0.9	2.4	1.7	1.3	1.3

Merck (MRK), Pfizer (PFE), Abbott Laboratories (ABT), Medtronic (MDT)

Probability-weighted DCF: We analyze multiple scenarios for the base business using a DCF valuation, and we then apply probabilities to those scenarios to arrive at a probability-weighted fair value. The scenarios range from a blue sky, which contemplates upside to consensus estimates down to a black swan, which assumes deterioration in the base business. We then calculate the valuation implied by our predicted fair value on our basic model estimates looking at PE, EV/EBITDA and EV/sales. Similar to the findings from our comp table, we find only modestly positive risk/reward based on valuation alone.

4 Outcome Scenarios and Fair Value

risk reward	Price	Price Δ %	Probability	weighted Δ%	discount rate	Scenario Assumptions
current price	\$147					Base Business
scenario 1	\$211	44%	15%	6.6%	8%	Blue Sky
scenario 2	\$184	25%	35%	8.9%	9%	>Consensus
scenario 3	\$145	-1%	35%	-0.4%	9%	<Consensus
scenario 4	\$123	-16%	15%	-2.4%	10%	Deterioration
Probability-weighted Fair Value	\$165					
Δ% from current price	13%					
Fair Value Implied Valuation	2020	2021				
PE	21.6	18.4				
EV / EBITDA	16.6	14.4				
EV / Sales	5.7	5.2				



Important Disclosure Information

The information contained in this report has been obtained from sources believed to be reliable, but is not necessarily complete and its accuracy cannot be guaranteed. All opinions, projections, estimates and prices reflected herein are as of the date of the report and are subject to change without notice. Information contained in this report may have been communicated to internal Northern Trust personnel prior to publication of the report and such personnel may have acted upon that information on behalf of Northern clients. Northern Trust is under no obligation to update this report and Northern Trust's ability to publish reports on the subject company (ies) in the future may be subject to restricted periods. You should therefore assume that Northern Trust will not update any fact circumstance or opinion contained in this report. Certain outstanding reports may contain discussions and/or investment opinions relating to securities that are no longer current. Always refer to the most recent report relating to a security prior to making an investment decision. The information contained herein may become unreliable because of subsequent market conditions, economic circumstances or for other reasons.

Materials prepared by Northern Trust personnel are based on public information. Facts and views presented in this material have not been reviewed by and may not reflect information known to, professionals in other business areas of Northern Trust. Northern Trust, through various of its business units, may have issued and may in the future issue reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Such ideas or recommendations reflect the different time frames, assumptions, views and analytical methods of the persons who prepared them, and Northern Trust is under no obligation to ensure that such other trading ideas or recommendations are brought to the attention of any recipient of this report.

This report is for information purposes only and is not intended as an offer or solicitation with respect to the purchase or sale of any security, and should not be construed as a recommendation for any security. This report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this report and should understand that statements regarding future prospects may not be realized. Any decision to purchase or sell securities must be based solely on existing public information on such security. This report has been prepared independently of any issuer of securities mentioned herein and not in connection with any proposed offering of securities or as agent of any issuer of any securities.

Northern Trust, its affiliates, and their respective officers, directors, clients, where it acts as agent or fiduciary, and employees, including persons involved in the preparation of this report, may from time to time have a position in, or buy and sell, the securities mentioned herein. Neither Northern Trust, nor any director, officer or employee of Northern Trust, accepts any liability, whatsoever, for any direct, indirect or consequential damages or losses arising from any use of this report or its contents.

Any information relating to the tax status of financial instruments discussed herein is not intended to provide tax advice or to be used by anyone to provide tax advice. Investors are urged to seek tax advice based on their particular circumstances from an independent tax professional. Levels and basis for taxation may change.

To the extent this report discusses any legal proceeding or issues, it has not been prepared as nor is it intended to express any legal conclusion, opinion or advice. Investors should consult their own legal advisers as to issues of law relating to the subject matter of this report. Northern Trust's research personnel's knowledge of legal proceedings in which any Northern Trust entity and/or its directors, officers and employees may be plaintiffs, defendants, co-defendants or co-plaintiffs with or involving companies mentioned in this report is based on public information. Facts and views presented in this material that relate to any such proceedings have not been reviewed by, discussed with, and may not reflect information known to, professionals in other business areas of Northern Trust in connection with the legal proceedings or matters relevant to such proceedings.

Securities discussed in this report are not deposits of any bank and are not insured or guaranteed by the Federal Deposit Insurance Corporation, any other government agency, or Northern Trust, or its affiliates and subsidiaries. Investments in general involve numerous risks, including market risk. Past performance is not necessarily a guide to future performance.

This report is prepared for the use of Northern Trust clients and may not be redistributed, retransmitted or disclosed, in whole or in part, or in any form or manner, without the express consent of Northern Trust. Any unauthorized use or disclosure is prohibited. Receipt and review of this research report constitutes your agreement not to redistribute, retransmit, or disclose to others the contents, opinions, conclusion, or information contained in this report (including any investment recommendations, estimates or price targets) without first obtaining expressed consent from an authorized officer of Northern Trust.

Consensus data is supplied by FactSet Estimates. The "Stock Performance" price/volume chart is provided by FactSet Research Systems. The "Company Profile" is provided by FactSet Fundamentals.

The Northern Trust Company, 50 South LaSalle Street, Chicago, Illinois 60603, (312) 630-6000.